创伤性脑损伤患者伤前使用直接口服抗凝药的后果:系统评价与荟萃分析
该研究为系统评价与荟萃分析,检索了PubMed、Embase、Web of Science和Cochrane Library,最终纳入6篇文章。比较伤前使用直接口服抗凝药(DOAC)与维生素K拮抗剂(VKA)的创伤性脑损伤(TBI)患者,基线及急诊科参数相似。荟萃分析显示,两组院内死亡率(OR 0.98,95%CI 0.23-4.06;I²=76%;p=0.97)、神经外科干预(OR 0.48,95%CI 0.14-1.63;p=0.24)及颅内出血进展率(OR 1.86,95%CI 0.32-10.66;p=0.49)均无显著差异。结论认为,使用DOAC的轻型TBI患者与使用VKA者相比,似乎不增加院内死亡、颅内出血进展或手术风险。
要点
- 荟萃分析显示,伤前使用DOAC与VKA的TBI患者院内死亡率无显著差异(OR 0.98,95%CI 0.23-4.06;I²=76%;p=0.97)。
- 神经外科干预率在DOAC组与VKA组间无显著差异(OR 0.48,95%CI 0.14-1.63;p=0.24)。
- 颅内出血进展率在DOAC组与VKA组间无显著差异(OR 1.86,95%CI 0.32-10.66;p=0.49)。
- 各原始研究中手术率、逆转药物使用、颅内出血进展及院内死亡率在DOAC与VKA队列间存在显著差异。
- 结论认为,使用DOAC的轻型TBI患者与使用VKA者相比,似乎不增加院内死亡、颅内出血进展或手术风险。
适用人群与场景
- 创伤性脑损伤(TBI)患者,伤前使用直接口服抗凝药(DOAC)或维生素K拮抗剂(VKA)。
- 纳入研究中包括轻型TBI患者(结论部分提及)。
研究设计与关键结果
- 研究类型:系统评价与荟萃分析;检索PubMed、Embase、Web of Science和Cochrane Library,筛选1,446篇摘要,最终纳入6篇文章。
- 所有队列基线及急诊科参数相似。
- 各原始研究中手术率、逆转药物使用、颅内出血进展及院内死亡率在DOAC与VKA队列间存在显著差异。
- 荟萃分析(随机效应模型):院内死亡率DOAC vs VKA的OR 0.98(95%CI 0.23-4.06;I²=76%;p=0.97),无显著差异。
- 神经外科干预率DOAC vs VKA的OR 0.48(95%CI 0.14-1.63;p=0.24),无显著差异。
- 颅内出血进展率DOAC vs VKA的OR 1.86(95%CI 0.32-10.66;p=0.49),无显著差异。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,证据等级 level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,使用DOAC的轻型TBI患者与使用VKA者相比,似乎不增加院内死亡、颅内出血进展或手术风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The rapid adoption and widespread use of direct oral anticoagulants (DOACs) has outpaced research efforts to establish their effects in bleeding trauma patients. In patients with complicated traumatic brain injury (TBI) caused by intracranial hemorrhage, DOAC use may be associated with higher bleeding volume and potentially more disastrous sequelae than use of vitamin K antagonists (VKAs). In the current systematic review and meta-analysis we set out to evaluate the literature on the relationship between preinjury DOAC use and course of the intracranial hemorrhage. (ICH), its treatment and mortality rates in TBI patients, and to compare these outcomes to those of patients with preinjury VKA use.
METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched using a search strategy including three main terms: "traumatic brain injury," "direct oral anticoagulants," and "vitamin K antagonists." There were 1,446 abstracts screened, and ultimately, six included articles. Random effects modeling meta-analysis was performed on in-hospital mortality, ICH progression and neurosurgical intervention rate.
RESULTS: All cohorts had similar baseline and emergency department parameters. Within individual studies surgery rate, reversal agents used, ICH progression and in-hospital mortality differed significantly between DOAC and VKA cohorts. Meta-analysis showed no significant difference in in-hospital mortality (odds ratio [OR], 0.98; 95% confidence interval [CI], 0.23-4.06; I = 76%; p = 0.97), neurosurgical interventions (OR, 0.48; 95% CI, 0.14-1.63; p = 0.24), or ICH progression rates (OR, 1.86; 95% CI, 0.32-10.66; p = 0.49) between patients that used preinjury DOACs versus patients that used VKAs.
CONCLUSION: Direct oral anticoagulant-using mild TBI patients do not appear to be at an increased risk of in-hospital mortality, nor of increased ICH progression or surgery rates, compared with those taking VKAs.
LEVEL OF EVIDENCE: Systematic review, level III.
参考来源
- Nederpelt CJ, van der Aalst SJM, Rosenthal MG, et al. Consequences of pre-injury utilization of direct oral anticoagulants in patients with traumatic brain injury: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2020. PMID: 31688828. doi:10.1097/TA.0000000000002518
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。